BD Vacutainer EDTA Blood Collection Tube (Lavender — K2EDTA, Haematology)
Pack Sizes Available
Product Description
Technical Specifications
- Brand and Additive: BD Vacutainer K2EDTA Blood Collection Tube; BD (Becton, Dickinson); K2EDTA (dipotassium EDTA) dry spray-coated on interior tube walls at 1.8 mg EDTA per ml blood (ISO 6710 standard); lavender/purple BD Hemogard closure; PET plastic
- Available Volumes: 2ml (13x75mm, REF 367835) | 3ml (13x75mm, REF 367836) | 4ml (13x75mm, REF 367843) | 6ml (13x75mm, REF 367863) | 10ml (16x100mm, REF 366643/368589); all calibrated vacuum draw; EDTA amount scales with volume (e.g., 10.8mg in 6ml tube)
- Primary Applications: Complete Blood Count (CBC) with automated differential; blood film morphology; HbA1c; reticulocyte count; haemoglobinopathy screening; blood group/crossmatch; malaria testing; DNA/RNA extraction for molecular diagnostics; flow cytometry; ESR (some protocols)
- Mixing Requirement: Invert gently 8-10 times immediately after collection; distribute K2EDTA uniformly to ensure complete anticoagulation; do NOT shake vigorously (haemolysis risk); sample stable at room temp for CBC analysis within 4-6 hours; blood film should be made within 2-4 hours for optimal morphology
- Regulatory Status: FDA cleared; CE marked; ISO 13485 certified BD manufacturing; ISO 6710 EDTA concentration compliant; CDSCO compliant India; BD Hemogard closure reduces stopper blood contact; latex-free components; for in vitro diagnostic use only
Frequently asked questions
The BD Vacutainer K2EDTA tube is the required or preferred collection tube for a wide range of haematological and molecular tests. Key tests include: Complete Blood Count (CBC) with automated differential — the most ordered blood test globally; manual blood film examination for morphology review; reticulocyte count; ESR (in certain protocol); HbA1c (glycated haemoglobin for diabetes monitoring); haemoglobinopathy screening including sickle cell, thalassaemia, and haemoglobin electrophoresis; malaria blood film (thick and thin) and malaria antigen testing; blood group ABO and Rh typing; antibody screening and crossmatch for blood bank; DNA/RNA extraction for PCR-based molecular diagnostics, genetic testing, and infectious disease molecular assays; and flow cytometry immunophenotyping. EDTA is contraindicated for coagulation studies and most clinical chemistry panels where cellular contamination would affect results.
K2EDTA (dipotassium EDTA) is supplied as a dry spray-coat on the tube walls at 1.8 mg EDTA per millilitre of blood — the ISO 6710 standard concentration. K3EDTA (tripotassium EDTA) is supplied as a liquid solution inside the tube. Both chelate calcium to prevent clotting, but K3EDTA liquid dilutes the blood sample by approximately 1-3% and its higher osmolality can cause erythrocyte shrinkage, leading to falsely low MCV and MCHC values. K2EDTA dry spray-coat introduces no liquid dilution, preserves accurate red cell volume measurements, and is the CLSI and ISO recommended formulation for haematological testing. BD has transitioned its primary EDTA tube range to K2EDTA dry spray-coat precisely because it produces more accurate haematological results.
BD Vacutainer K2EDTA tubes are available in: 2ml (13x75mm, REF 367835) — neonatal and paediatric, minimum blood volume; 3ml (13x75mm, REF 367836) — paediatric and small-volume adult draws; 4ml (13x75mm, REF 367843) — standard adult CBC and most haematology tests; 6ml (13x75mm, REF 367863) — standard adult with multiple haematology tests from one tube; 10ml (16x100mm, REF 366643) — high-volume adult, research, and multiple tests combined. Tube size selection should balance the volume required for ordered tests, patient age and venous access, and the rule that EDTA tubes must be filled within ±10% of stated draw volume — under-filling changes the EDTA-to-blood ratio, causing erythrocyte shrinkage and falsely low haematocrit.
EDTA is superior to heparin for haematological specimen preparation because it preserves leukocyte and erythrocyte morphology more reliably at room temperature for the time between collection and analysis. Heparin causes two known morphological artefacts: leukocyte clumping (making automated differential counts unreliable and manual review difficult) and a blue cytoplasmic granularity artefact in neutrophils and other leukocytes on Romanowsky-stained blood films. EDTA does not cause these effects at the correct 1.8 mg/ml concentration. Platelets remain as countable individuals in EDTA rather than forming aggregates (as they can in suboptimally anticoagulated heparin samples). At room temperature, EDTA blood can typically be analysed reliably within 4-6 hours of collection, with morphology suitable for blood film review for up to 2-4 hours post-collection.
Yes, EDTA anticoagulated whole blood is appropriate for blood bank pre-transfusion testing. ABO blood grouping, Rh typing, antibody screening (indirect antiglobulin test), and crossmatch procedures all use EDTA samples. EDTA is compatible with the wash procedures used in blood bank serology. Blood bank protocols typically require samples drawn within a defined window before the scheduled transfusion (commonly 72-96 hours for patients without recent transfusion history) to ensure the crossmatch reflects current antibody status. Some blood bank protocols require a dedicated tube drawn specifically for blood bank use, separate from other laboratory tubes, to maintain clear chain of custody and prevent sample mix-up. Always follow local blood bank collection and labelling protocols.
BD specifies that EDTA blood collection tubes should be inverted gently 8 to 10 times immediately after blood collection. This is the CLSI-recommended inversion count for EDTA tubes. The purpose is to dissolve the dry spray-coated K2EDTA from the tube walls into the blood and distribute it uniformly throughout the sample, ensuring complete and even anticoagulation. Insufficient mixing (fewer than 8 inversions) leaves areas of the sample inadequately anticoagulated, risking fibrin microclot formation that can clog haematology analyser probes and produce falsely low platelet counts. Vigorous shaking is harmful because it causes haemolysis (ruptures red blood cells), which interferes with haemoglobin, plasma potassium, LDH, and other measurements. Gentle end-over-end inversion at the specified count is the correct technique.
Microlisa HIV Ag & Ab 4th Generation ELISA Test Kit
Blood screening exists in a category of laboratory work where the margin for error is not just professionally unacceptable but medically catastrophic. A false negative in HIV screening does not just fail a test. It compromises patient safety, undermines transfusion protocols, and exposes healthcare systems to risks that nobody wants to calculate. Microlisa HIV Ag & Ab 4th Generation ELISA was engineered to close the detection window that makes early HIV infection so difficult to identify reliably. This is an in-vitro qualitative enzyme immunoassay designed for simultaneous detection of antibodies to HIV-1 (including Group O and subtype C prevalent in India), HIV-2, and HIV-1 p24 antigen in human serum or plasma. The test is intended for screening of blood donors, diagnostic testing of individuals at risk for HIV infection, and clinical evaluation of patients with AIDS-related symptoms. It represents the fourth generation of HIV ELISA technology, which detects both antibodies and antigens simultaneously rather than antibodies alone. The clinical advantage of 4th generation testing is the shortened window period. Traditional antibody-only tests miss early seroconversion cases where HIV-1 p24 antigen is present but antibodies have not yet developed to detectable levels. By detecting p24 antigen during the acute infection phase (typically 2 to 4 weeks post-exposure), this assay identifies infections approximately 1 to 2 weeks earlier than 3rd generation antibody-only tests. That earlier detection matters critically in blood donor screening and post-exposure monitoring. The assay is based on sandwich ELISA methodology. Microtiter wells are pre-coated with HIV envelope proteins (gp41, C-terminus of gp120 for HIV-1, and gp36 for HIV-2) and anti-p24 monoclonal antibodies. When specimens are added, any HIV antibodies or p24 antigen present bind to the coated antigens or antibodies. After washing, horseradish peroxidase (HRPO) conjugated antigens and anti-p24 antibodies are added, forming a sandwich complex. The colorimetric reaction develops proportionally to the amount of HIV antibodies or antigen present, read at 450nm absorbance. The kit uses color-coded reagents to monitor procedural steps, reducing protocol errors during multi-step workflows. Breakaway microwell strips allow testing flexibility from single specimens to full 96-well plate runs. Storage stability is maintained at 2-8°C with a shelf life of 24 months unopened. Total assay time including incubation steps is approximately 120 minutes. Sensitivity and specificity meet international standards for 4th generation HIV screening. Clinical evaluations demonstrate 100% sensitivity in detecting seroconversion panels and p24 antigen standards quantified down to 200 pg/ml. Specificity exceeds 99.5% when tested against large sample populations. The test detects all major HIV-1 subtypes including Group O and subtype C, which are epidemiologically significant in the Indian subcontinent. For distributors supplying blood banks, transfusion centers, diagnostic laboratories, and public health screening programs, Microlisa HIV Ag & Ab represents a clinically validated 4th generation screening platform with predictable reorder cycles. Sara Wellness has been exporting in-vitro diagnostic kits and laboratory reagents from India for 15 years.
Advantage PAN Malaria Card Rapid Diagnostic Test Kit
Malaria diagnosis in endemic regions operates under time pressure that microscopy cannot always accommodate. A patient presenting with fever in a rural health center at midnight does not have the luxury of waiting until morning for a trained microscopist to arrive, prepare slides, and spend twenty minutes examining blood films under oil immersion. That delay can mean the difference between timely artemisinin treatment and cerebral malaria developing overnight. Advantage PAN Malaria Card was designed to deliver species-level diagnosis in settings where microscopy is impractical or unavailable. This is a rapid visual immunoassay for qualitative detection of all four human Plasmodium species (P. falciparum, P. vivax, P. malariae, P. ovale) based on pan-specific plasmodium lactate dehydrogenase (pLDH) antigen in whole blood. The test provides results within 20 minutes using a simple fingerstick blood sample, no laboratory equipment required, making it ideal for point-of-care testing in primary health centers, rural clinics, field hospitals, and outbreak response settings. The assay is based on sandwich immunochromatography using monoclonal antibodies specific to pLDH, an enzyme produced by all Plasmodium species during their erythrocytic life cycle. When infected blood is added to the test device and assay buffer is applied, red blood cells lyse and pLDH antigen (if present) binds to gold-conjugated anti-pLDH antibodies. This complex migrates along the nitrocellulose membrane and is captured by immobilized anti-pLDH antibodies at the test line, producing a visible pink-purple band that confirms malaria infection. The see-through device design allows direct visualization of sample migration and result development, which helps identify invalid tests caused by insufficient sample volume or improper application. This transparency reduces the ambiguity that plagues some lateral flow devices where internal workings are hidden. Sensitivity and specificity have been validated through WHO malaria RDT evaluation programs using panels of wild and cultured parasites. The test detects parasitemia levels above 100 parasites per microliter of blood for both P. falciparum and P. vivax, which is clinically relevant for symptomatic infections requiring treatment. Specificity exceeds 99% when tested against cross-reactive conditions including dengue, leptospirosis, typhoid, and other febrile illnesses common in malaria-endemic areas. Shelf life is 24 to 30 months when stored at 4-30°C, which is critical for stockpiling in tropical climates where cold chain infrastructure is unreliable. The extended temperature stability means the test remains functional even when stored at ambient temperatures in resource-limited settings. Each kit contains individually sealed test devices, buffer vials, blood collection pipettes, and instructions for use. The test requires no special training beyond basic clinical skills and can be performed by nurses, paramedics, or trained community health workers. For distributors supplying national malaria control programs, public health departments, NGO field operations, and private diagnostic laboratories, Advantage PAN Malaria Card represents a WHO-evaluated rapid diagnostic platform with predictable consumption tied to malaria case loads. Sara Wellness has been exporting rapid diagnostic test kits and laboratory reagents from India for 15 years.
Human Serum Coombs Antisera (Antihuman Globulin Reagent)
Blood banking operates on a fundamental requirement that most people never think about until something goes wrong. Every unit of blood transfused must be confirmed compatible with the recipient's immune system. Every pregnant woman screened for antibodies that could harm her unborn child. Every suspected case of hemolytic anemia investigated for antibodies attacking the patient's own red blood cells. None of this happens without Coombs antisera making the invisible antibodies visible. Human Serum Coombs Antisera is the reagent that makes antiglobulin testing possible in blood banks and immunohematology laboratories worldwide. This is antihuman globulin (AHG) reagent used in both direct and indirect antiglobulin tests (Coombs tests) to detect antibodies and complement components bound to red blood cell surfaces or present free in serum. The reagent is produced by immunizing animals (typically rabbits) with human immunoglobulins, which induces production of polyclonal antibodies specific for human IgG antibodies and complement factor C3d. When added to washed red blood cells coated with IgG or complement, the antihuman antibodies bind to the human antibodies and form bridges between adjacent sensitized cells, causing visible agglutination. The direct antiglobulin test (DAT) detects antibodies or complement already bound to red blood cell surfaces in vivo. This test is critical for diagnosing autoimmune hemolytic anemia, investigating hemolytic transfusion reactions, and diagnosing hemolytic disease of the fetus and newborn. The indirect antiglobulin test (IAT) detects free antibodies circulating in serum or plasma. This test is essential for pre-transfusion antibody screening, crossmatching blood units for compatibility, and prenatal antibody screening in pregnant women. Polyspecific Coombs antisera (like the green-colored reagent shown) contains antibodies against both IgG and C3d complement, providing broad-spectrum detection. When the polyspecific reagent produces a positive result, monospecific antisera (anti-IgG alone or anti-C3d alone) are used for follow-up testing to characterize whether red cells are coated with IgG antibodies, complement, or both. This differentiation is clinically important because it helps determine the cause and clinical significance of the positive test. The reagent is typically dyed green using patent blue and tartrazine to allow easy visual identification during laboratory workflows where multiple reagents are used simultaneously. Storage at 2-8°C maintains reagent potency until the expiration date printed on the bottle, typically 18 to 24 months from manufacture. The reagent contains sodium azide (0.1% w/v) as a preservative, which inhibits bacterial growth but requires careful handling and disposal. Each dropper bottle delivers approximately 40 microliters per drop, allowing precise volumetric dosing during testing. The reagent must not be diluted and should not be used if turbid, as turbidity indicates bacterial contamination or protein aggregation that will compromise test performance. For distributors supplying blood banks, hospital transfusion services, reference immunohematology laboratories, and donor screening centers, Coombs antisera represents an essential reagent with consumption directly tied to transfusion volume and prenatal screening programs. Sara Wellness has been exporting immunohematology reagents and blood banking supplies from India for 15 years.